Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 6 of 6 entries
Sorted by: Best Match Show Resources per page
Preparation and Distribution of Cannabis and Cannabis-Derived Dosage Formulations for Investigational and Therapeutic Use in the United States.

Frontiers in pharmacology

Thomas BF, Pollard GT.
PMID: 27630566
Front Pharmacol. 2016 Aug 31;7:285. doi: 10.3389/fphar.2016.00285. eCollection 2016.

Cannabis is classified as a schedule I controlled substance by the US Drug Enforcement Agency, meaning that it has no medicinal value. Production is legally restricted to a single supplier at the University of Mississippi, and distribution to researchers...

Cite
Thomas BF, Pollard GT. Preparation and Distribution of Cannabis and Cannabis-Derived Dosage Formulations for Investigational and Therapeutic Use in the United States. Front Pharmacol. 2016;7:285doi: 10.3389/fphar.2016.00285.
Thomas, B. F., & Pollard, G. T. (2016). Preparation and Distribution of Cannabis and Cannabis-Derived Dosage Formulations for Investigational and Therapeutic Use in the United States. Frontiers in pharmacology, 7285. https://doi.org/10.3389/fphar.2016.00285
Thomas, Brian F, and Pollard, Gerald T. "Preparation and Distribution of Cannabis and Cannabis-Derived Dosage Formulations for Investigational and Therapeutic Use in the United States." Frontiers in pharmacology vol. 7 (2016): 285. doi: https://doi.org/10.3389/fphar.2016.00285
Thomas BF, Pollard GT. Preparation and Distribution of Cannabis and Cannabis-Derived Dosage Formulations for Investigational and Therapeutic Use in the United States. Front Pharmacol. 2016 Aug 31;7:285. doi: 10.3389/fphar.2016.00285. eCollection 2016. PMID: 27630566; PMCID: PMC5006560.
Copy Download .nbib Format: NLM
Vaping Synthetic Cannabinoids: A Novel Preclinical Model of E-Cigarette Use in Mice.

Substance abuse : research and treatment

Lefever TW, Marusich JA, Thomas BF, Barrus DG, Peiper NC, Kevin RC, Wiley JL.
PMID: 28469427
Subst Abuse. 2017 Apr 07;11:1178221817701739. doi: 10.1177/1178221817701739. eCollection 2017.

Smoking is the most common route of administration for cannabis; however, vaping cannabis extracts and synthetic cannabinoids ("fake marijuana") in electronic cigarette devices has become increasingly popular. Yet, most animal models used to investigate biological mechanisms underlying cannabis use...

Cite
Lefever TW, Marusich JA, Thomas BF, et al. Vaping Synthetic Cannabinoids: A Novel Preclinical Model of E-Cigarette Use in Mice. Subst Abuse. 2017;11:1178221817701739doi: 10.1177/1178221817701739.
Lefever, T. W., Marusich, J. A., Thomas, B. F., Barrus, D. G., Peiper, N. C., Kevin, R. C., & Wiley, J. L. (2017). Vaping Synthetic Cannabinoids: A Novel Preclinical Model of E-Cigarette Use in Mice. Substance abuse : research and treatment, 111178221817701739. https://doi.org/10.1177/1178221817701739
Lefever, Timothy W, et al. "Vaping Synthetic Cannabinoids: A Novel Preclinical Model of E-Cigarette Use in Mice." Substance abuse : research and treatment vol. 11 (2017): 1178221817701739. doi: https://doi.org/10.1177/1178221817701739
Lefever TW, Marusich JA, Thomas BF, Barrus DG, Peiper NC, Kevin RC, Wiley JL. Vaping Synthetic Cannabinoids: A Novel Preclinical Model of E-Cigarette Use in Mice. Subst Abuse. 2017 Apr 07;11:1178221817701739. doi: 10.1177/1178221817701739. eCollection 2017. PMID: 28469427; PMCID: PMC5398321.
Copy Download .nbib Format: NLM
Toxic by design? Formation of thermal degradants and cyanide from carboxamide-type synthetic cannabinoids CUMYL-PICA, 5F-CUMYL-PICA, AMB-FUBINACA, MDMB-FUBINACA, NNEI, and MN-18 during exposure to high temperatures.

Forensic toxicology

Kevin RC, Kovach AL, Lefever TW, Gamage TF, Wiley JL, McGregor IS, Thomas BF.
PMID: 30705707
Forensic Toxicol. 2019 Jan;37(1):17-26. doi: 10.1007/s11419-018-0430-0. Epub 2018 Jun 28.

PURPOSE: The use of novel synthetic cannabinoids as intoxicants continues in spite of associated health risks. These compounds are typically smoked or vaporized, but many synthetic cannabinoids contain thermally labile chemical moieties. This study investigated the thermal stability six...

Cite
Kevin RC, Kovach AL, Lefever TW, et al. Toxic by design? Formation of thermal degradants and cyanide from carboxamide-type synthetic cannabinoids CUMYL-PICA, 5F-CUMYL-PICA, AMB-FUBINACA, MDMB-FUBINACA, NNEI, and MN-18 during exposure to high temperatures. Forensic Toxicol. 2018;37(1):17-26doi: 10.1007/s11419-018-0430-0.
Kevin, R. C., Kovach, A. L., Lefever, T. W., Gamage, T. F., Wiley, J. L., McGregor, I. S., & Thomas, B. F. (2019). Toxic by design? Formation of thermal degradants and cyanide from carboxamide-type synthetic cannabinoids CUMYL-PICA, 5F-CUMYL-PICA, AMB-FUBINACA, MDMB-FUBINACA, NNEI, and MN-18 during exposure to high temperatures. Forensic toxicology, 37(1), 17-26. https://doi.org/10.1007/s11419-018-0430-0
Kevin, Richard C, et al. "Toxic by design? Formation of thermal degradants and cyanide from carboxamide-type synthetic cannabinoids CUMYL-PICA, 5F-CUMYL-PICA, AMB-FUBINACA, MDMB-FUBINACA, NNEI, and MN-18 during exposure to high temperatures." Forensic toxicology vol. 37,1 (2019): 17-26. doi: https://doi.org/10.1007/s11419-018-0430-0
Kevin RC, Kovach AL, Lefever TW, Gamage TF, Wiley JL, McGregor IS, Thomas BF. Toxic by design? Formation of thermal degradants and cyanide from carboxamide-type synthetic cannabinoids CUMYL-PICA, 5F-CUMYL-PICA, AMB-FUBINACA, MDMB-FUBINACA, NNEI, and MN-18 during exposure to high temperatures. Forensic Toxicol. 2019 Jan;37(1):17-26. doi: 10.1007/s11419-018-0430-0. Epub 2018 Jun 28. PMID: 30705707; PMCID: PMC6349387.
Copy Download .nbib Format: NLM
Thermal Degradants Identified from the Vaping of Vitamin E Acetate.

Journal of analytical toxicology

Kovach AL, Carter RR, Thornburg JW, Wiethe R, Fennell TR, Wiley JL.
PMID: 34666345
J Anal Toxicol. 2021 Oct 20; doi: 10.1093/jat/bkab109. Epub 2021 Oct 20.

Studies have suggested that vitamin E acetate (VEA), when used in an electronic vaping device, undergoes thermal degradation and is considered one of the main contributors in E-cigarette or Vaping product use-Associated Lung Injury (EVALI). Using a Borgwaldt 5.1...

Cite
Kovach AL, Carter RR, Thornburg JW, et al. Thermal Degradants Identified from the Vaping of Vitamin E Acetate. J Anal Toxicol. 2021;doi: 10.1093/jat/bkab109.
Kovach, A. L., Carter, R. R., Thornburg, J. W., Wiethe, R., Fennell, T. R., & Wiley, J. L. (2021). Thermal Degradants Identified from the Vaping of Vitamin E Acetate. Journal of analytical toxicology, . https://doi.org/10.1093/jat/bkab109
Kovach, Alexander L, et al. "Thermal Degradants Identified from the Vaping of Vitamin E Acetate." Journal of analytical toxicology vol. (2021). doi: https://doi.org/10.1093/jat/bkab109
Kovach AL, Carter RR, Thornburg JW, Wiethe R, Fennell TR, Wiley JL. Thermal Degradants Identified from the Vaping of Vitamin E Acetate. J Anal Toxicol. 2021 Oct 20; doi: 10.1093/jat/bkab109. Epub 2021 Oct 20. PMID: 34666345.
Copy Download .nbib Format: NLM
In vitro and in vivo pharmacokinetics and metabolism of synthetic cannabinoids CUMYL-PICA and 5F-CUMYL-PICA.

Forensic toxicology

Kevin RC, Lefever TW, Snyder RW, Patel PR, Fennell TR, Wiley JL, McGregor IS, Thomas BF.
PMID: 28824730
Forensic Toxicol. 2017;35(2):333-347. doi: 10.1007/s11419-017-0361-1. Epub 2017 Mar 10.

CUMYL-PICA [1-pentyl-

Cite
Kevin RC, Lefever TW, Snyder RW, et al. In vitro and in vivo pharmacokinetics and metabolism of synthetic cannabinoids CUMYL-PICA and 5F-CUMYL-PICA. Forensic Toxicol. 2017;35(2):333-347doi: 10.1007/s11419-017-0361-1.
Kevin, R. C., Lefever, T. W., Snyder, R. W., Patel, P. R., Fennell, T. R., Wiley, J. L., McGregor, I. S., & Thomas, B. F. (2017). In vitro and in vivo pharmacokinetics and metabolism of synthetic cannabinoids CUMYL-PICA and 5F-CUMYL-PICA. Forensic toxicology, 35(2), 333-347. https://doi.org/10.1007/s11419-017-0361-1
Kevin, Richard C, et al. "In vitro and in vivo pharmacokinetics and metabolism of synthetic cannabinoids CUMYL-PICA and 5F-CUMYL-PICA." Forensic toxicology vol. 35,2 (2017): 333-347. doi: https://doi.org/10.1007/s11419-017-0361-1
Kevin RC, Lefever TW, Snyder RW, Patel PR, Fennell TR, Wiley JL, McGregor IS, Thomas BF. In vitro and in vivo pharmacokinetics and metabolism of synthetic cannabinoids CUMYL-PICA and 5F-CUMYL-PICA. Forensic Toxicol. 2017;35(2):333-347. doi: 10.1007/s11419-017-0361-1. Epub 2017 Mar 10. PMID: 28824730; PMCID: PMC5519669.
Copy Download .nbib Format: NLM
Interactions of Cannabinoids With Biochemical Substrates.

Substance abuse : research and treatment

Thomas BF.
PMID: 28607542
Subst Abuse. 2017 May 29;11:1178221817711418. doi: 10.1177/1178221817711418. eCollection 2017.

Recent decades have seen much progress in the identification and characterization of cannabinoid receptors and the elucidation of the mechanisms by which derivatives of the

Cite
Thomas BF. Interactions of Cannabinoids With Biochemical Substrates. Subst Abuse. 2017;11:1178221817711418doi: 10.1177/1178221817711418.
Thomas, B. F. (2017). Interactions of Cannabinoids With Biochemical Substrates. Substance abuse : research and treatment, 111178221817711418. https://doi.org/10.1177/1178221817711418
Thomas, Brian F. "Interactions of Cannabinoids With Biochemical Substrates." Substance abuse : research and treatment vol. 11 (2017): 1178221817711418. doi: https://doi.org/10.1177/1178221817711418
Thomas BF. Interactions of Cannabinoids With Biochemical Substrates. Subst Abuse. 2017 May 29;11:1178221817711418. doi: 10.1177/1178221817711418. eCollection 2017. PMID: 28607542; PMCID: PMC5457144.
Copy Download .nbib Format: NLM
Showing 1 to 6 of 6 entries